�Actelion Ltd (SWX: ATLN) announced that Tracleer� (bosentan), a double endothelin sense organ antagonist, has been sanctioned in the European Union for the treatment of patients with mildly symptomatic pulmonary arterial hypertension (PAH WHO functional class FC II). Since 2002, Tracleer� has been approved and available in the European Union for PAH patients with WHO FC III.
Tracleer� is the first PAH discourse ever to be investigated in a clinical survey that entirely enrolled patients with mildly symptomatic WHO FC II. This 185-patient randomized, double blind, placebo-controlled l to the pathophysiology of systemic sclerosis (SSc) and pivotal in the development of PAH in SSc, one of the leading causes of
